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Editor’s key points
† Perioperative anaemia is
common in patients
presenting for major
surgery.
† Blood transfusion has
traditionally been the
treatment, but this has a
number of problems.
† Patient blood
management aims to
minimize the need for
transfusion.
† Early detection and
treatment of anaemia
and minimizing blood
loss are key strategies.
Summary. Preoperative anaemia is common in patients undergoing orthopaedic and other
major surgery. Anaemia is associated with increased risks of postoperative mortality and
morbidity, infectious complications, prolonged hospitalization, and a greater likelihood of
allogeneic red blood cell (RBC) transfusion. Evidence of the clinical and economic
disadvantages of RBC transfusion in treating perioperative anaemia has prompted
recommendations for its restriction and a growing interest in approaches that rely on
patients’ own (rather than donor) blood. These approaches are collectively termed
‘patient blood management’ (PBM). PBM involves the use of multidisciplinary, multimodal,
individualized strategies to minimize RBC transfusion with the ultimate goal of improving
patient outcomes. PBM relies on approaches (pillars) that detect and treat perioperative
anaemia and reduce surgical blood loss and perioperative coagulopathy to harness and
optimize physiological tolerance of anaemia. After the recent resolution 63.12 of the
World Health Assembly, the implementation of PBM is encouraged in all WHO member
states. This new standard of care is now established in some centres in the USA and
Austria, in Western Australia, and nationally in the Netherlands. However, there is a
pressing need for European healthcare providers to integrate PBM strategies into routine
care for patients undergoing orthopaedic and other types of surgery in order to reduce
the use of unnecessary transfusions and improve the quality of care. After reviewing
current PBM practices in Europe, this article offers recommendations supporting its wider
implementation, focusing on anaemia management, the first of the three pillars of PBM.
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Anaemia affects1.6 billion people, 25% of the world’s popula-
tion.1 Iron deficiency is the principal cause of anaemia1 and is a
major contributory factor to the global disease burden.2
Anaemia, which can be due to underlying conditions or surgical
blood loss, is commonly found in patients undergoing surgery.3
Major orthopaedic surgery is associated with substantial blood
loss, leading to a significant decrease in haemoglobin (Hb)
levels during surgery.4 5 A recent meta-analysis of 19 studies
showed that 24% of patients undergoing total hip replacement
(THR) or total knee replacement (TKR) and 44% of those with hip
fracture had preoperative anaemia. As these procedures are
associated with considerable blood loss (mean 1500 ml),6 7
after operation, 51% of patients undergoing THR/TKR and 87%
of patients with hip fracture were anaemic.5 Between 22% and
75% of patients undergoing colorectal surgery and 34% of
those undergoing other forms of non-cardiac surgery have
also been reported to have preoperative anaemia.3 In a recent
multicentre cohort study, the prevalence of preoperative
anaemia in cardiac surgery patients ranged from 22% to
30%.8 Preoperative anaemia in patients undergoing major
surgery is often caused by chronic disease, but hypochromic/
microcytic anaemia may require iron studies.9 10
Prospective and retrospective cohort studies have consist-
ently shown that patients with preoperative anaemia have
poorer postoperative outcomes than non-anaemic patients.
Early data suggested that severe preoperative anaemia
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(Hb ,8 g dl21) independently predicted postoperative mor-
tality in patients undergoing various unspecified types of
surgery.11 12 A recent retrospective cohort study demon-
strated a higher postoperative 30 day morbidity and mortal-
ity in patients who underwent major non-cardiac surgery
with preoperative anaemia than in those without
anaemia.13 In elderly patients with hip fracture, anaemia
(Hb ,12 g dl21 for females and ,13 g dl21 for males) was
significantly associated with 2- to 5- and 3-fold increases in
the multivariate-adjusted risk of 6 and 12 month mortality,
respectively.14 Patients with Hb ,10 g dl21 were at a 5-fold
increased risk of death. Subsequent studies have confirmed
the association between preoperative anaemia and post-
operative mortality in this population,15 16 and in patients
undergoing other types of surgery.3 17 18 In addition to mor-
tality, preoperative anaemia is also significantly and inde-
pendently associated with increased morbidity, including
the elevated risk of infectious complications and a prolonga-
tion of postoperative hospital stay.14 – 16 19 Some studies have
linked perioperative anaemia to impaired postoperative func-
tional recovery after surgery for hip fracture,15 16 20 although
it was not an independent factor in a prospective multivari-
ate analysis.16 In addition, anaemia is a risk factor for both
early and late mortality in patients undergoing coronary
artery bypass grafting (CABG).21
Transfusion may be regarded as the default therapy for
anaemia, as it is considered as safe and is rapidly effective.
However, accumulating, there is increasing evidence that
the correction of preoperative anaemia using transfusion is
associated with risks that may contribute to morbidity and
mortality in surgical patients.22 23 Consequently, there is in-
creasing recognition of new approaches to the management
of anaemia, collectively referred to as patient blood manage-
ment (PBM).5 22 24 25 This article, based on discussions held
by a panel of expert anaesthetists, surgeons, and nurses,
explores the risks associated with the use of red blood cell
(RBC) transfusions in the management of perioperative
anaemia, primarily in orthopaedic surgery, and the role of
PBM in improving the quality of care in this setting. It also
highlights examples of successful PBM programmes, over-
views current practice patterns in Europe, and offers recom-
mendations for supporting the wider implementation of PBM.
Transfusion and preoperative anaemia
The Orthopaedic Surgery Transfusion Haemoglobin European
Overview (OSTHEO) study prospectively analysed blood
management data from 3996 patients undergoing elective
orthopaedic surgery in Europe in 1999.26 Data were collected
from 225 centres in France, Germany, Greece, Italy, the
Netherlands, and Spain. Overall, 69% of patients received
transfusion, including 35% who received autologous
transfusions only and 25% who received allogeneic blood
transfusions (ABTs) only.
Around 45% of major orthopaedic surgery patients receive
perioperative RBC transfusion.5 Orthopaedic surgery is the
leading surgical indication for transfusion, accounting for
10% of all RBC units transfused.27 28 Patients with preopera-
tive anaemia are more likely to receive perioperative blood
transfusions in the setting of orthopaedic,4 9 10 14 19 26 29 30
and other types of surgery,17 30 than non-anaemic patients.
For example, in 1142 patients undergoing elective hip or
knee surgery in the UK in 2000–1, 42.0% of anaemic patients
received a transfusion compared with 21.3% of patients
overall, and a preoperative Hb level of,11.0 g dl21 was strong-
ly and independently associated with transfusion (odds ratio
13.92; P,0.001).10 In a prospective, observational Austrian
study, the main predictors for allogeneic RBC transfusions
were preoperative and lowest Hb and surgical blood loss.30
The use of ABTs to correct anaemia in surgical patients is
not supported by evidence of benefit. Transfusions increase
Hb levels in critically ill patients, but they do not appear to re-
liably improve tissue oxygenation.31 32 ABTs are associated
with a number of risk factors that can be divided into
transfusion-transmitted infectious complications (e.g. HIV
and hepatitis), immunological complications [e.g. immuno-
modulation resulting in postoperative infection, sepsis,
antibody-mediated alloimmunization, graft-vs-host disease
(GVHD), haemolytic transfusion reactions, and allergic reac-
tions], transfusion-related acute lung injury (TRALI; which
has both immunological and non-immunological properties),
and non-infectious non-immunological complications (e.g.
acute lung injury, transfusion errors, non-haemolytic and
haemolytic reactions, circulatory overload, and metabolic
disturbances).22 23
Cohort studies have documented an increased risk of
infectious complications, fluid overload, delay in wound
healing, and prolonged hospital stay in transfused patients
undergoing orthopaedic surgery.29 33 – 36 Adverse transfusion
outcomes have also been documented in critically ill patients,
trauma patients, and cardiac or colorectal surgery.37
Observational studies have found higher postoperative
mortality rates in transfused patients undergoing cardiac
surgery compared with those who were not transfused, even
after adjustment for other risk factors.38 Randomized con-
trolled trials (RCTs) in patients undergoing cardiac surgery
have shown that white blood cell (WBC)-reduced blood pro-
ducts carry a lower mortality risk than non-WBC-reduced pro-
ducts.23 However, this has not been observed after other types
of surgery, and this issue is not resolved.23
TRALI, acute transfusion reactions, haemolytic transfusion
reactions, transfusion-transmitted infections, circulatory over-
load, and (in the UK) transfusion-associated GVHD are the
main causes of death and morbidity related to ABT.39 40
TRALI has a presentation similar to acute respiratory distress
syndrome, which has also been linked to transfusion.41
Different models have been proposed for the pathogenesis
of TRALI.42 43 An antibody-mediated immune reaction,
whereby antibodies in donated plasma activate recipient
neutrophils within the lung, has been proposed.43 Alterna-
tively, the ‘two-event’ model proposes that factors present
in transfused stored blood products trigger TRALI in patients
in whom endothelial activation is already present due to an
initial proinflammatory event, for example, infection, surgery,
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or trauma.42 Transfusion-related immunomodulation pro-
poses that deleterious proinflammatory effects result from
a complex interplay between transfusion effects, genetic
factors, intercurrent illnesses, and inflammatory mediators
and effector cells.44
However, a causal relationship between transfusion and
these serious complications is not established. Much of the
evidence for these complications comes from retrospective,
uncontrolled, non-randomized, observational cohort studies
that may be subject to bias and confounding factors, and
predominantly demonstrate correlations rather than causal
relationships. Patients who are less well relative to healthy
patients are more likely to receive transfusion. Thus, transfu-
sion may be a surrogate for other causes of poor outcome.
However, the association between allogeneic RBC transfu-
sions and adverse outcome has been shown so consistently
over the last three decades, that causation is highly
likely.45 46
The storage of donated RBCs has enabled a more efficient
use of blood supplies. However, allogeneic blood undergoes
changes during prolonged storage (storage lesions), which
may affect patient outcome. These changes include the ac-
cumulation of proinflammatory metabolic and breakdown
products (e.g. lysophospholipids) that may be linked to
TRALI, changes in cell shape, acidosis, membrane loss,
haemolysis, increased rigidity, and stronger endothelial
attachment.44 47 Some studies have correlated the use of
older, stored RBCs with an increased risk of complications
and mortality in cardiac surgery and trauma patients.48 49
However, the impact of storage on post-surgical outcome is
a matter of debate.44 The evidence supporting this associ-
ation comes from observational studies that could be
subject to bias and confounding factors. Some studies have
reported that the storage age of RBCs was not independently
associated with poorer outcomes,50 while a recent
meta-analysis concluded that the available data do not
support an association between older RBCs and increased
morbidity or mortality.51
The risks of transfusion are acknowledged by the American
Association of Blood Banks, American Blood Commission,
and American Red Cross.52 The 2009 International Consen-
sus Conference on Transfusion and Outcomes (ICCTO;
Phoenix, AZ, USA) concluded that, based on available
evidence and considering a number of scenarios in which
transfusions are commonly given, ABT is not likely to
improve patient outcome in most scenarios (but may even
cause harm). The impact of ABT on patient outcomes
remains uncertain and in need of further investigation,
providing a rationale for more judicious use of ABT.53 54
Additional disadvantages with the use of transfusions
relate to scarcity and cost of blood. The supply of blood for
transfusions is limited by an ageing population and increas-
ingly restrictive screening criteria. The chain of supply can
also be overwhelmed by disaster events, potentially leading
to blood shortages at the local level. While more blood
may be donated in response to disaster events, the daily
supply margin is limited and days during which there is a
sudden increase in the use can disrupt the blood supply.
While this may be a problem in developing nations, it
may still affect first-world countries with established
infrastructure.22 The increasing scarcity of blood and
measures to reduce the risks of infection transmission have
increased the direct costs of transfusion.55 The true costs of
transfusion services are likely to have been underestimated
owing to their complexity. A detailed study of the costs asso-
ciated with all activities involved in providing transfusion ser-
vices in surgical patients in four hospitals in the USA, Austria,
and Switzerland recently estimated expenditures ranging
from $1.62 to $6.03 million per hospital. The total costs
were 3- to 5-fold higher than blood product acquisition
costs alone.56 Indirect costs have previously associated
with the legal ramifications of contaminated blood supplies,
and also the personal costs to affected donors and
patients.56 – 58
Despite the risks, limited benefits, costs, and scarcity, a
substantial proportion of RBC transfusions given today may
not be appropriate or justified according to the report of
the ICCTO panel and several reports on variable transfusion
practices in otherwise comparable populations.53 These find-
ings support a more cautious transfusion strategy than the
current system. A retrospective study in two US hospitals
found a significant correlation between inadequate or sub-
optimal documentation and failure to justify transfusion,
with 73% of inadequately documented transfusions not
meeting hospital guidelines.59 Inappropriate transfusion
practices may endanger patients and waste resources. A
recent RCT demonstrated that a liberal transfusion strategy
(a higher Hb threshold of 10 g dl21) did not improve out-
comes (death, inability to walk independently at a 60 day
follow-up and in-hospital mordibity) compared with a re-
strictive strategy (Hb threshold of ,8 g dl21), in a population
of high-risk patients after hip-fracture surgery.60
Patient blood management
The clinical, logistic, and economic disadvantages of RBC
transfusion have prompted recommendations for its restric-
tion, particularly unnecessarily transfused stored blood54—
and an interest in new approaches.5 23 24 37 The concept of
PBM (or ‘blood conservation’) has been developed to
promote ‘the appropriate provision and use of blood, its com-
ponents and derivatives, and strategies to reduce or avoid
the need for a blood transfusion’.61 However, the concept
has been developed with more emphasis on preventative
measures and improving patient outcome. PBM relies on
three key strategies to achieve its goals: optimize the patient’s
own RBC mass, minimize blood loss, and harness and optimize
physiological tolerance of anaemia.24 27 Therefore, PBM
requires a multidisciplinary, multimodal, individualized
strategy for avoiding and controlling blood loss, and to system-
atically identify, evaluate, and manage anaemia (Fig. 1).62
Patient blood management in Europe BJA
57
 at U
niversitaet Zuerich on D
ecem
ber 28, 2012
http://bja.oxfordjournals.org/
D
ow
nloaded from
 
Perioperative measures
Before operation, PBM involves a careful assessment of
bleeding risk and anaemia well in advance of surgery (e.g.
30 days) to allow full evaluation and correction of anaemia.
This has been specifically recommended in patients undergo-
ing orthopaedic surgery.63 The patient’s own blood should be
conserved by restricting blood drawn for tests and by restrict-
ing the use of antiplatelet and anticoagulant agents to situa-
tions where these drugs are indicated. Pharmacological and
mechanical venous thromboembolism prophylaxis measures
are both widely used in patients undergoing THR and TKR,
with recommendations of better compliance with estab-
lished evidence-based guidelines.64 Autologous preoperative
donation was once promoted to decrease the need for ABT.
However, predonated blood is also subject to storage
lesion, and is labour intensive, expensive, and inefficient,
with almost half of predonated autologous units not
used.29 Some patients may not be able to predonate blood
due to comorbidities and current or potential anaemia.3
There are possible deleterious effects of blood storage for
units predonated weeks ahead of surgery.24
It has been suggested that Hb levels before elective ortho-
paedic surgery should be within the normal range defined by
the World Health Organization (WHO; ≥12 g dl21 in women;
≥13 g dl21 in men).61 Iron supplementation should be used
to correct iron deficiency. Oral iron is effective in reducing the
need for transfusion before orthopaedic surgery.65 66
Erythropoiesis-stimulating agents (ESAs) may need to be
added in patients with preoperative anaemia.66 Data from
prospective, non-randomized case series suggest that i.v.
iron can correct iron deficiency anaemia before elective
orthopaedic surgery67 and reduce rates of ABT, postoperative
infection, and mortality in patients with hip fracture, com-
pared with historical controls.68 69 Another case series
found that the perioperative use of i.v. iron in conjunction
with ESA therapy in anaemic patients with hip fracture (Hb
levels of ,13 g dl21) reduced the proportion of patients
requiring transfusion, the number of units transfused, and
• Screen for anaemia
• Identify underlying disorder(s) causing 
anaemia
• Manage underlying disorder(s)
• Refer for further evaluation if necessary
• Treat iron deficiency, anaemia of chronic
  disease, iron-restricted erythropoiesis
• Note: anaemia is a contraindication for 
elective surgery
• Identify and manage bleeding risk   
(past/family history, current medications, 
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• Minimise iatrogenic blood loss
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2nd Pillar
Minimise blood loss and bleeding
• Assess/optimise patient’s physiological 
reserve and risk factors
• Compare estimated blood loss with 
patient-specific tolerable blood loss
• Formulate patient-specific management 
plan using appropriate blood-conservation 
modalities to minimise blood loss, optimise 
red cell mass and manage anaemia
• Restrictive evidence-based transfusion 
strategies
 
• Timing surgery with haematological 
optimisation
• Meticulous haemostasis and surgical 
techniques
• Blood-sparing surgical techniques
• Anaesthetic blood-conserving strategies
• Autologous blood options
• Pharmacological/haemostatic agents
• Optimise cardiac output
• Optimise ventilation and oxygenation
• Restrictive evidence-based transfusion 
strategies
 
• Treat anaemia/iron deficiency
• Stimulate erythropoiesis
• Be aware of drug interactions that can 
cause/increase anaemia
• Vigilant monitoring and management of 
post-operative bleeding
• Avoid secondary haemorrhage
• Rapid warming – maintain normothermia 
(unless hypothermia specifically indicated)
• Autologous blood salvage
• Minimising iatrogenic blood loss
• Haemostasis/anticoagulation management
• Prophylaxis of upper gastrointestinal 
haemorrhage
• Avoid/treat infections promptly
• Be aware of adverse effects of medication
• Optimise tolerance of anaemia
• Treat anaemia
• Maximise oxygen delivery
• Minimise oxygen consumption
• Avoid/treat infections promptly
• Restrictive, evidence-based transfusion 
strategies
3rd Pillar
Harness and optimise tolerance 
of anaemia
Fig 1 A multimodal approach to PBM (or blood conservation). Adapted from Hofmann and colleagues62 with permission. ESA, erythropoiesis-
stimulating agents.
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the rate of postoperative infections compared with a parallel
control group. There was no difference in the 30 day mortal-
ity or the mean duration of hospitalization.70 Previous recom-
mendations that patients with preoperative anaemia due to
iron deficiency or chronic disease may receive preoperative
treatment with i.v. or oral iron, depending on the timing of
surgery, the patient’s tolerance of oral iron, and iron
status,71 72 are based on low-to-moderate-quality evidence.
Further RCTs of i.v. iron are currently underway.
ESA therapy may be used within PBM strategies. ESA
increases Hb and reduces the need for transfusion in patients
undergoing orthopaedic and cardiac surgeries.3 5 24 62 73 It
has been suggested that ESA should be used in anaemic
patients in whom iron deficiency anaemia has been ruled
out or corrected.63 Iron supplementation plus ESA corrected
normocytic anaemia due to chronic disease in preoperative
orthopaedic surgery patients;10 this can lead to increased
transfusion avoidance.10 74 Patients should receive iron sup-
plementation (preferably i.v.) throughout the use of ESA to
avoid functional iron deficiency.63 73 A recent study evalu-
ated a blood conservation protocol involving a restrictive
transfusion trigger (Hb ,8 g dl21) and perioperative adminis-
tration of i.v. iron with (n¼115) or without (n¼81) ESA in
patients undergoing hip fracture repair.75 Patients who
received ESA therapy together with i.v. iron had a significantly
lower allogeneic transfusion rate (60% vs 42%, P¼0.013) and
higher postoperative Hb than those who received iron alone,
but there was no difference in postoperative complications
or 30 day mortality rate. The combination of a restrictive Hb
trigger, i.v. iron, and ESA reduced the use of ABT in patients
(n¼139) undergoing TKR surgery.76 In this study, patients
who received unwashed shed blood after operation (if their
preoperative Hb was ,13.0 g dl21), in addition to ESA and
i.v. iron, showed a significantly reduced hospital stay com-
pared with those who received i.v. iron and ESA alone
(P,0.05). A more conservative use has been advocated
because of concerns about side-effects of ESAs. After regula-
tory changes in the light of safety concerns, the use of ESA has
significantly decreased in cancer centres, but no effect was
seen on transfusions.77 These changes in usage may impact
upon individual PBM strategies, as alternatives to ESA
become important.
Intraoperative measures to prevent blood loss include
patient positioning and the use of electrocautery, tourni-
quets, vasoconstrictors, and topical or systemic (e.g. tranex-
amic acid epsilon aminocaproic acid, aprotinin, and
desmopressin) and local haemostatic agents.22 24 25 78 – 80
Acute normovolaemic haemodilution, where blood is col-
lected of the operation for potential transfusion after oper-
ation and replaced by a crystalloid or colloid solution, can
be used to lessen the loss of RBCs and clotting factors
during bleeding. Reviews of the use of colloids and crystal-
loids have shown that while there is no difference in overall
patient survival between the two forms, specific products
are best suited to certain situations.81 82 Autologous blood
cell salvage is particularly useful for procedures involving
massive blood loss and in patients who object to the use of
ABT. Postoperative measures include close monitoring of
bleeding and anaemia and the continuing various measures
described above.24 27 Individual blood conservation
approaches may each save 1–2 units of blood, and when
multiple approaches are used together, 2 units of blood
can usually be saved.24 25
Implementation and effectiveness of PBM programmes
A cluster randomization study in Canadian hospitals demon-
strated that a multicomponent blood conservation algorithm
reduced the use of ABT and increased ESA use in orthopaedic
surgery patients.83 Similarly, in France, a blood conservation
algorithm introduced in one orthopaedic unit in 2005
changed local practice, reducing the overall use of transfu-
sions by 56% and wastage of autologous blood units by
50% (P¼0.002), and increasing the rate of ESA usage (from
6.6 to 17.3%; P,0.05). These changes were associated
with a 50% reduction in hospital costs that offset the costs
associated with increased ESA usage, resulting in no signifi-
cant change in overall costs.84
There is increasing awareness of the need to integrate
PBM within routine surgical care. PBM has been successfully
implemented in some centres in the USA.25 The Government
of Western Australia has implemented PBM state-wide as the
standard of care.80 The Australian Red Cross has also issued
guidance on measures to reduce the need for ABT, including
in surgical patients.85
Current European PBM practice
Overview
The implementation of PBM in Europe has been variable and
inconsistent (Tables 1 and 2). While some countries, such as
the Netherlands, have been using some PBM strategies for a
decade, other countries have adopted few, if any, of these
measures. Notably, no widely accepted guidelines exist to
aid the process of PBM implementation.
Typically, anaesthetists, surgeons, or both are responsible
for the preoperative assessment of anaemia in patients
undergoing surgery. However, as in the Netherlands, other
healthcare personnel may be included as part of a multidis-
ciplinary approach. Variations exist between countries in the
reported or estimated prevalence rates of preoperative
anaemia and in the extent to which it is investigated. The
timeframes for the preoperative assessment of anaemia
appear to vary from 1 day to 6 weeks before surgery.
Shorter timeframes restrict the treatment of preoperative
anaemia, because of the pressure not to delay surgery.
There also appears to be considerable variation in the
availability and use of guidelines for preoperative anaemia
treatment and transfusion between countries. The reported
frequency of transfusion in orthopaedic surgery in hospitals
ranges from ,2 to 40%30 (Tables 1 and 2).
Austria
Patterns of blood use in patients undergoing surgery for
THR/TKR were documented by the Austrian Benchmark
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Study, a prospective observational study in 18 hospitals
between 2004 and 2005.29 Preoperative anaemia was
3-fold more common in patients who received transfusions
compared with those who did not receive transfusions
(28.6% vs 6.7% in patients undergoing THR, 29.9% vs 9.3%
in TKR, 33.1% vs 12.6% in CABG). Variations were observed
between centres in the number of RBCs transfused, the use
of blood salvage, and the return of shed blood. The second
Austrian benchmark study confirmed that anaemic patients
received transfusions twice as often as non-anaemic
patients, and up to four times as many transfusions (unpub-
lished data; personal communication of H.G., P.H. Rehak, A.S.,
and A.H.).
There are no national guidelines for the management of
preoperative anaemia or transfusion guidelines. However,
treatment is guided by algorithms, and includes iron and
vitamin B12 supplementation as necessary (Table 2). The
transfusion guidelines of the ASA are followed.86 PBM strat-
egies are established in only a few hospitals in Austria, and
broad implementation is necessary.
France
Hb is typically measured 2 or 30 days before operation
(Table 1). Preoperative anaemia is not usually investigated
further. French guidelines87 recommend the use of ESA,
with iron supplementation, when Hb is ≤13 g dl21, although
this is limited predominantly to hip surgery. I.V. iron is indi-
cated for the correction of postoperative anaemia when
oral iron is insufficient or not well tolerated. Some institutions
customize ESA use, but 50% do not treat anaemia before
operation.
As described above, at least one report of the successful
implementation of a PBM algorithm in France has been pub-
lished, showing a reduction in transfusions and an increase in
the use of ESA with no increase in overall costs.84
Germany
There appears to be limited awareness or appreciation of the
problem of preoperative anaemia in this setting in Germany.
Anaemia is generally assessed the day before surgery and is
usually investigated further if Hb is ,8 g dl21. No preopera-
tive anaemia treatment guidelines exist, and transfusion
guidelines are determined locally by hospitals.
Spain
The risk of transfusion varies according to the patient’s level
of preoperative anaemia (Table 1). The rate of transfusion in
Spain varies significantly between centres and surgical
teams; as such, rates for the country as a whole are uncer-
tain. Orthopaedic surgery patients undergo a comprehensive
preoperative assessment and, if present, preoperative
anaemia is usually investigated further (Table 2).
No specific national guidelines for preoperative
anaemia exist, although an algorithm is used where PBM is
implemented.88 Transfusion is normally recommended for
patients with Hb ,7 g dl21, but this threshold can be
,10 g dl21 in patients with active bleeding or who are
receiving chemotherapy (Table 2).89
Switzerland
The prevalence of preoperative anaemia in patients undergo-
ing THR or TKR surgery in Switzerland is 16–21% with
transfusion rates of 19–22% in primary repair surgery
and 30240% in surgical revisions.67 Various laboratory
tests, including iron status tests, are performed by primary-
care physicians/surgeons in the days or weeks before
surgery (Table 2), although less severe anaemia (Hb 10–13
g dl21) may often be missed. Recommended transfusion trig-
gers depend on the type of surgery (e.g. Hb,6 g dl21 in
obstetrics, ,7 g dl21 in general surgery, and ,8 g dl21 in
Table 1 Estimates of preoperative anaemia prevalence and transfusion rates in orthopaedic surgery patients in selected European countries.
ESA, erythropoiesis-stimulating agents; Hb, haemoglobin; THR, total hip replacement; TKR, total knee replacement
Country Prevalence of preoperative anaemia Frequency of transfusion use
Austria 16–18% TKR¼41.3% (varied from 12% to 87% between centres);
THR¼42.5% (varied from 16% to 85% between centres); ,10%
receive predonated autologous blood; patients with anaemia
receive 2× amount of blood received by those without anaemia
France Estimate: 20% (no precise data) Estimate: 40% (despite ESA use)
Germany Not known Not known
Spain In general, 18.3% (but almost one-third of patients
have Hb levels of ,13 g dl21)91
Transfusion risk (varies among centres): Hb ≤10 g dl21: 93.2%;
Hb=14 g dl21: 19.75%; Hb=13 g dl21: 40%
Switzerland Estimates in selected centres: 16–21% Estimates in selected centres: primary repair: 19–22%; repeat
operations: 30–40%
The Netherlands Estimate of anaemia (Hb levels of ,13 g dl21):
15–20% for major orthopaedic surgery
TKR,2%; THR,5%
UK ,12 g dl21 in 15% and ,13 g dl21 in 37% of
patients (within 28 days of surgery)
57% of patients with a preoperative Hb level of ,12 g dl21; 20%
of patients with a preoperative Hb level of ≥12 g dl21
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Table 2 PBM practices in orthopaedic surgery in selected European countries. COX, cyclo-oxygenase; CRP, C-reactive protein; EPO, recombinant
human erythropoietin; ESA, erythropoiesis-stimulating agents; Hb, haemoglobin; MCH, mean corpuscular haemoglobin; MCV, mean cell volume;
NSAID, non-steroidal anti-inflammatory drugs; PBM, patient blood management; SOC, standard of care; TBC, total blood count; TSAT, transferrin
saturation
Country Assessment procedures,
responsible person, and
haematological parameters
If present, is
preoperative anaemia
investigated further?
Anaemia management Are PBM strategies in place for
major elective surgery?
Austria Complete preoperative investigation
performed at clinic visit 4 weeks
before surgery, with preparation for
anaesthesia and implementation of
PBM
Yes Dependent on algorithm
and laboratory testing
Yes, but only in a few hospitals
Tests: TBC, followed by MCV,
creatinine, ferritin depending on Hb
Iron supplementation if
MCV,80 fl, ferritin ,100
ng litre21, transferrin
saturation ,20%
Vitamin B12 if MCV .100 fl
Responsible person:
anaesthetist
France Patient assessed 2 days before
operation when no planned
indication for ESA, 30 days before
operation when ESA planned
Usually not Usually intra- or
postoperative transfusion
to address anaemia
No
Tests: Hb concentration only,
platelet count
Preoperative transfusion
only when anaemia is
profound or if surgery is
delayed/cancelled (rare)
Responsible person: anaesthetist ESA are used mainly in hip
surgery
Responsible person:
anaesthetist
Germany Patients usually assessed the day
before surgery
Usually, if Hb level is
,8 g dl21
When transfusion is
performed, erythrocyte
concentrates are usually
given
No
Tests: Hb, haematocrit, platelet
parameters, electrolytes
Responsible persons:
surgeons (before and after
operation), anaesthetist
(intraoperatively)
Responsible person: surgeon
Spain Patients assessed 4–6 weeks before
surgery (average 30 days)
Usually Analysis of patient’s
condition
Yes, including the following:
Tests: Hb, reticulocyte count, MCH,
MCV, % of hypochromic
erythrocytes, vitamin B12, folic acid,
iron indices (ferritin, TSAT). Other
tests include medical history and
bleeding tendency, viral infections,
drugs, previous transfusion, body
weight and height, ASA status, ECG,
X-ray (optional), general lab tests
Analysis of transfusion risk Correction with iron and vitamin
supplementation, and ESA before
elective surgery
Anaemia part of systematic protocol
for all major elective orthopaedic
surgery
Review of laboratory tests Discontinuation of anticoagulants
and antiplatelet agents before
elective surgery, when this
measure is safe
Responsible person: anaesthetist Date of surgery considered Autologous blood predonation in
complex surgery
Responsible person: usually
anaesthetist (in some
cases, haematologist)
Use of better anaesthetic and
surgical techniques to minimize
blood loss during surgery
Continued
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Table 2 Continued
Country Assessment procedures,
responsible person, and
haematological parameters
If present, is
preoperative anaemia
investigated further?
Anaemia management Are PBM strategies in place for
major elective surgery?
Use of pharmacological strategies
with proven efficacy
Optimal control of coagulation
Minimize blood sample
extractions for laboratory use
Intraoperative blood collection
and reinfusion of blood loss during
surgery
Switzerland Lab tests (including Hb, MCV, ferritin,
TSAT, and CRP) performed by
primary care physician/surgeons
days/week before surgery
Yes 1–1.5 g iron
carboxymaltose for ‘pure’
iron deficiency anaemia
Yes, in limited number of hospitals
Hb measured on the day before
surgery
40 000 units EPO added to
i.v. iron for ‘combined’
forms of anaemia
University Hospital of Zurich:
introduction of PBM in
orthopaedic surgery has been
agreed, including change in
logistics to see all patients
(surgeons and anaesthesiologist)
4 weeks before surgery.
Coagulation management and
perioperative thromboembolic
prophylaxis in discussion, with a
governmental grant received
Blood volume calculation: takes
account of patient’s blood volume,
Hb transfusion trigger, and expected
blood loss based on each centre’s
data
All: 1 mg vitamin B12 i.m.
(once); 3×5 mg folic acid
(oral)
Responsible person: anaesthetist
and surgeon
Patients re-evaluated after
2 weeks, redoes i.v. iron
and EPO: CAVE Hb should
not become .15 g dl21
Responsible person: in the
future—anaesthetist (and
surgeon) with GP
The Netherlands Complete preoperative assessment
(3–4 weeks before surgery): medical
history, physical exam, drug history,
laboratory tests (Hb and MCV)
Hb level of ,10 g dl21
and/or MCV ,80 fl:
further investigation
and referral to internal
medicine
By law, a preoperative
assessment must be
performed (3–4 weeks
before surgery)
Yes (over last 10 yr)
Responsible person: anaesthetist,
nurse anaesthetist, resident
surgeon, pharmacy assistant
Surgery cancelled until
outcome known
Inspected by Health
Authority every year
Preoperative: ESA, COX-2-selective
NSAIDs
NEN-EN-ISO 9001: 2000
certified
Perioperative: surgery technique,
temperature, transfusion trigger
Expected blood loss for
surgery calculated (0.5–1.5
litre total loss in hip/knee
surgery)
Postoperative: cell-saving
(BellovacTM ABT), transfusion
trigger
Patients with Hb of 10–13
g dl21 received ESA plus
iron
Responsible person:
anaesthetist
Continued
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traumatic brain injury) and on the stability of the patient.
PBM strategies are in place in a limited number of hospitals.
The Netherlands
Dutch hospitals began to implement PBM 10 yr ago, espe-
cially for major orthopaedic surgery (Table 2). There is a legal
requirement for a complete preoperative assessment 3–4
weeks before all elective surgery. Importantly, anaesthetists
can cancel surgery until the outcome of treatment for
anaemia is known. Preoperative PBM precautions include
the use of cyclooxygenase-2-selective non-steroidal anti-
inflammatory drugs to reduce the risk of bleeding after
taking known risk factors into consideration.90 – 93 The intro-
duction of ESA use for patients undergoing other surgery
types is likely to occur in the future. National transfusion trig-
gers were instituted in 2000 (e.g. Hb of 6.4 g dl21 for normal
healthy patients).
All hospitals in the Netherlands report transfusion rates in
knee and hip surgery, and these can be compared on the
central website of the Dutch Health Authority.94 The results
of national surveys of Dutch orthopaedic surgery depart-
ments performed in 2002 and 2007 have documented the in-
creasing use of PBM measures to avoid transfusion.95 The use
of preoperative autologous blood donation was similar in
2002 and 2007 for both hip and knee arthroplasty (Fig. 2).
However, the preoperative use of ESA approximately
doubled between 2002 and 2007, while the use of post-
operative autologous cell salvage increased by 4- to 5-fold.
Smaller increases were observed in the use of intraoperative
autologous cell salvage.
Annual reports from the Dutch blood bank Sanquin96
showed a decline in the total number of allogeneic transfu-
sions by 12% in the period from the year 2000 to 2009
(Fig. 3). This decrease was concurrent with an increase in
healthcare usage. Hospital admissions increased from 1600
to 2300 per year per 10 000 inhabitants from 2000 to 2009.
Based on the current price of an allogeneic transfusion of
RBCs at E204, PBM is estimated to have saved a net cost of
E100 million nationwide every year.
Table 2 Continued
Country Assessment procedures,
responsible person, and
haematological parameters
If present, is
preoperative anaemia
investigated further?
Anaemia management Are PBM strategies in place for
major elective surgery?
UK Preoperative clinic scheduled 2–6
weeks before all elective surgery
Usually not. If
unexpected anaemia
identified patient
referred back to general
practitioner for
investigation
Patient cross-matched for
anticipated blood
transfusion requirement
Some centres now developing
pilot studies on PBM in the UK
Tests: Hb electrolytes, ECG, or per
departmental/procedural protocol.
Complex patients identified from
clinic are seen in pre-assessment by
anaesthetists.
Protocols established to withhold
anticoagulation and antiplatelet
therapy before operation
Investigation of anaemia not part of
current SOC
Intraoperative cell salvage used in
major non-oncological surgery
Tranexamic acid increasingly used
in significant haemorrhage
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Fig 2 Results of a national survey of rates of autologous pre-
operative blood donation, erythropoietin use, and autologous
retransfusion in patients undergoing (A) hip or (B) knee arthro-
plasty in 2002 and 2007 in the Netherlands.91
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United Kingdom
In the UK, elective surgery patients attend a pre-admission
clinic for review 2–6 weeks before operation where routine
health checks and blood tests, ECG, and, where appropriate,
anaesthetic review are undertaken.97 The aim of
pre-assessment is to reduce hospital stay by facilitating
admission on the day of operation, and to reduce the risk
of operative cancellations (Table 2). An internal audit at
one UK centre prospectively reviewed all patients admitted
for elective operation over a 4 month period. Of 1532
patients seen in all specialties, preoperative anaemia was
present in 252 (16%). Most patients had a normocytic nor-
mochromic pattern with one-third having iron deficiency
(ferritin ,30 ng litre21 with hypochromia or microcytosis).
The perioperative transfusion rate was 26% in anaemic
patients and 5% in those with normal Hb levels. Both pre-
operative anaemia and transfusion were associated with
increased length of hospital stay.
A national comparative audit of blood use in elective
primary THR surgery was conducted in the UK in 2006–7.98
Data on 7465 patients from 225 hospitals were analysed.
Almost all of the participating hospitals performed preopera-
tive anaemia assessments, although 29% of patients did not
have a presurgery Hb level recorded. Fewer than half of the
hospitals (47%) had a transfusion policy. Overall, 25% of
patients were transfused within the period from 28 days pre-
surgery to 14 days postsurgery, but this figure varied from 0%
to 100% between hospitals. Data from pilot studies sug-
gested that PBM in anaemic patients before primary joint re-
placement or major abdominal surgery may reduce the need
for RBC transfusion by 30–40%. Translating these projections
to the National Health Service (NHS), 60 500 major
operations and 119 600 primary THR and TKR procedures
were projected. A reduction in RBC transfusion alone would
translate into the NHS saving £3 782 552, reducing hospital
stay by 1 day in 4.51% would equate to a saving of £14.3
million, and complications could be prevented in 5397
patients, saving £17.1 million. Overall, PBM could produce a
conservative annual saving of £35 million to the NHS. As
the audit is now several years old, it is worth noting that
some of these improvements and savings may have
already been made. An RCT is under consideration by the
National Institute for Health Research in the UK to further
assess the findings from these pilot studies.
A wider implementation of PBM within perioperative care
in European countries may be hindered by a variety of poten-
tial barriers. This group recommends that authorities respon-
sible for PBM implementation consider these barriers in
conjunction with a variety of recommendations to enable
an efficient implementation across Europe (Table 3).
In conclusion, there is an urgent need for European
healthcare providers to fully recognize the deleterious
effects of preoperative anaemia and the risks associated
with perioperative blood transfusion, and to integrate multi-
modal PBM strategies into routine care for patients undergo-
ing orthopaedic and other types of surgery. Implementing
PBM requires a paradigm shift in preoperative care whereby
anaemia is detected well in advance of elective surgery
and treated using effective measures that reduce the
requirement for blood transfusion and improve the quality
of care. Transfusion should be the last option in the treat-
ment of anaemia, rather than the first choice. The imple-
mentation of PBM requires liaison and partnership between
all personnel and organizations responsible for perioperative
care, including Blood Service authorities.
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Fig 3 Number of allogeneic transfusions in the Netherlands from 2000 to 2010.96
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Currently, the implementation of PBM in Europe is limited,
and considerable variations exist in the assessment and
treatment of preoperative anaemia. Lessons can be learned
from countries and centres where PBM has already been
integrated into routine practice, for example, in the USA,
Western Australia, and in the Netherlands. It is hoped that
this report also aids the wider implementation of PBM in
Europe.
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Table 3 Barriers to, and recommendations for, the implementation of PBM in Europe
Barriers to implementation of PBM Recommendations for implementation of PBM
Surgeons may not fully understand the clinical impact of anaemia
(including iron deficiency anaemia) and the effect of anaemia on
postoperative recovery
There is a need to increase knowledge and awareness of the clinical
implications of anaemia and the need for alternatives to transfusion,
with a focus on clinical outcomes, inappropriateness, cost, and supply
issues
Doctors, familiar with the ease and established use of blood transfusion,
may not appreciate the risks associated with transfusions or the role of a
restrictive transfusion practice (PBM)
Further high-quality data confirming the effectiveness of PBM
programmes in reducing complications and mortality, and the
cost-effectiveness of these programmes, are required
There is a lack of a standardized, accepted definition of preoperative
anaemia, and a paucity of widely accepted evidence-based PBM
guidelines/recommendations
Standardized algorithms for the definition and treatment of preoperative
anaemia in elective surgery are required to avoid a reliance solely on Hb
levels as a trigger. This is supported by findings from OSTHEO, in which
accurate assessment of preoperative Hb levels was found to contribute
to effective blood and anaemia management25
Patients often present at hospital for surgery without an early
preoperative assessment to allow the evaluation and correction of
anaemia
Early preoperative visits should be scheduled, in order to allow
preoperative anaemia to be corrected before surgery
There could be concerns that PBM may delay surgery (particularly
cardiac surgery)
There is a need to encourage a paradigm shift among physicians, with a
focus on the reporting of data on transfusion rates and patient outcomes
to encourage ‘healthy competition’ between institutions
There could be concerns that PBM may increase the risk of complications Documentation processes for PBM (including improved consent forms for
blood transfusion for example) are required
There is currently no RCT to support the use of PBM in elective surgery Incentives for the use of newer measures, and disincentives against
older practices, are required to ensure the implementation of PBM. The
benefits of PBM for healthcare professionals, in terms of personal
accomplishment, should also be communicated
Further data confirming the cost-effectiveness of PBM programmes are
required
Development of ‘centres of excellence’ for PBM, including clinical
champions
Individual hospital departments may fear the initial costs of
implementing PBM, even though PBM is expected to reduce longer-term
healthcare costs through lower direct expenditure, reduced
complications, and shorter hospitalization times
Creation of PBM registries for systematic data collection and evaluation
In some countries, the use of i.v. iron is not reimbursed (or its
reimbursement is limited to certain surgical indications), while each
transfusion is separately reimbursed
The reimbursement system should favour the use of PBM measures,
including early anaemia detection and treatment
In some countries, the established position of the blood services system
in hospitals and government may limit the scope for changes in the
management of blood components
There is a lack of trained personnel with expertise in PBM
The routine use of transfusion is a ‘habit’ and change is therefore limited
by clinical inertia
The personal benefit PBM offers to physicians is not well appreciated
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